Cerbios' new State-of the-art R&D Centre for HPAI and mAb Development
21.09.2016 -
-
(c) Cerbios Pharma SA -
(c) Cerbios Pharma SA
On February 15th, 2016, Cerbios Pharma officially opened its new R&D Centre in Lugano, Switzerland. During the past 15 years, Cerbios has heavily invested in infrastructures, in acquisitions and company participations driven by innovation and differentiation. This has not only more than doubled the company turnover which has also doubled the number of employees, but has also generated value in the Swiss Canton of Ticino, confirming a strong sustainability approach.
The construction of the R&D centre was approved in November 2013 and started in April 2014. Thanks to a favorable climate, the roof was built before Christmas 2014. Between January to October 2015 all interior was installed and the two HVACs on the roof (one fully dedicated to the CHO biotechnology laboratories) were tested and put in operation.
The new building consists of four floors of 280 m2 each (total 1’120 m2) that are set up as follows.
- 2nd Floor: Biological R&D, with three dedicated laboratories for the development of mAbs and/or recombinant proteins based on CHO mammalian cells and a large laboratory to develop pharmaceutical probiotics.
- 1st Floor: new additional GMP Archive, offices for the directors and for the managers of R&D and Quality Assurance
- Ground Floor: Chemical R&D, doubling the capacity to develop HPAIs (also known as HPAPIs) for contract manufacturing services including Safebridge® Category 4.
- Underground: Two warehouses (one for R&D and one for production) and the personnel services.
Cerbios specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide. Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.
The privately held, Lugano-based company provides full CMC support to its partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
